Literature DB >> 9749956

Changed expression of 9-O-acetyl GD3 (CDw60) in benign and atypical proliferative lesions and carcinomas of the human breast.

A Gocht1, G Rutter, B Kniep.   

Abstract

Expression of gangliosides is affected in various ways by malignant cell transformation. In the present study, we investigated the expression of CDw60, a constituent of O-acetylated disialogangliosides, in benign and atypical proliferative breast diseases, and preinvasive and invasive carcinomas by immunohistochemistry and thin-layer chromatography (TLC). In normal ducts, antibodies to CDw60 (mAb M-T21) reacted to membranes of the Golgi apparatus in the juxtaluminal cell compartment. A similar polarized distribution of Golgi cisterns in epithelial cells was observed in several benign lesions, i.e., fibroadenomas, intraductal papillomas, and gynecomastia. In contrast, blunt duct adenosis and duct hyperplasia exhibited an abnormal cytosolic and cell surface staining, whereas atypical duct hyperplasia showed randomly dispersed immunoreactive Golgi cisterns, indicating loss of epithelial polarity. In mammary carcinomas and in two breast carcinoma cell lines (MCF-7 and EFM-19) the neoplastic cells contained CDw60-immunolabelled Golgi complexes, which were distributed in a disorderly fashion throughout the cytoplasm, thus reflecting a loss of epithelial polarity. Additionally, only well differentiated ductal carcinomas in situ or invasive ductal carcinomas disclosed a strong cell surface labelling, which was absent in lower differentiated carcinomas of the same types. In all carcinomas, the intensity of CDw60 immunostaining decreased with progressing loss of differentiation (grade of dedifferentiation), as demonstrated by staining intensity in paraffin sections and by evaluation of the relative amounts of extracted 9-O-acetyl GD3 by TLC. Our results indicate that abnormal CDw60 expression is already detectable in benign proliferative breast lesions with different risk rates to develop into malignant lesions. Downregulation of CDw60 expression in poorly differentiated invasive carcinomas may be the consequence of loss of cell functions usually associated with poor prognosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9749956     DOI: 10.1007/s004180050284

Source DB:  PubMed          Journal:  Histochem Cell Biol        ISSN: 0948-6143            Impact factor:   4.304


  8 in total

1.  CDw60: an antigen expressed in many normal tissues and in some tumours.

Authors:  A Gocht; A Gadatsch; G Rutter; B Kniep
Journal:  Histochem J       Date:  2000-07

Review 2.  Gangliosides with O-acetylated sialic acids in tumors of neuroectodermal origin.

Authors:  Guido Kohla; Eggert Stockfleth; Roland Schauer
Journal:  Neurochem Res       Date:  2002-08       Impact factor: 3.996

3.  Carbohydrate post-glycosylational modifications.

Authors:  Hai Yu; Xi Chen
Journal:  Org Biomol Chem       Date:  2007-02-06       Impact factor: 3.876

Review 4.  Gangliosides: The Double-Edge Sword of Neuro-Ectodermal Derived Tumors.

Authors:  Sumeyye Cavdarli; Sophie Groux-Degroote; Philippe Delannoy
Journal:  Biomolecules       Date:  2019-07-27

Review 5.  Functions and Biosynthesis of O-Acetylated Sialic Acids.

Authors:  Chitra Mandal; Reinhard Schwartz-Albiez; Reinhard Vlasak
Journal:  Top Curr Chem       Date:  2015

6.  O-Acetylated sialic acids and their role in immune defense.

Authors:  Roland Schauer; G Vinayaga Srinivasan; Dirk Wipfler; Bernhard Kniep; Reinhard Schwartz-Albiez
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

Review 7.  Cancer-Associated Glycosphingolipids as Tumor Markers and Targets for Cancer Immunotherapy.

Authors:  Sophie Groux-Degroote; Philippe Delannoy
Journal:  Int J Mol Sci       Date:  2021-06-07       Impact factor: 5.923

8.  O-acetylated N-acetylneuraminic acid as a novel target for therapy in human pre-B acute lymphoblastic leukemia.

Authors:  Reshmi Parameswaran; Min Lim; Anna Arutyunyan; Hisham Abdel-Azim; Christian Hurtz; Kam Lau; Markus Müschen; Robert K Yu; Mark von Itzstein; Nora Heisterkamp; John Groffen
Journal:  J Exp Med       Date:  2013-03-11       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.